Klaus W. Wagner, M.D., Ph.D.

Chief Medical Officer

Klaus leads the clinical translation of Inhibrx’s biotherapeutic pipeline. Prior to joining Inhibrx, Klaus trained at M.D. Anderson Cancer Center as a fellow and worked at Banner M.D. Anderson Cancer Center as a medical oncologist, where he also served as the local principal investigator of cancer immunotherapy trials. Klaus’s scientific work at Genentech and the Genomics Institute of the Novartis Research Foundation (GNF) focused on drug discovery and predictive biomarker development. Klaus received the highest academic honors and was a Scholar of the German Merit Foundation. He received his M.D. and Ph.D. from the Friedrich-Alexander University of Erlangen in Germany.